Integrated DNA Technologies Executive and Leadership Team

Maz Mohadjer, the Chief Executive Officer at Integrated DNA Technologies, directs the overarching corporate strategy and long-term vision for the organization. Overseeing the alignment of manufacturing capabilities with the evolving needs of the biotechnology and pharmaceutical sectors, the Chief Executive Officer ensures consistent delivery of high-quality custom nucleic acids. This leadership role involves fostering partnerships across academic research institutions to accelerate scientific discovery. By prioritizing operational excellence and market expansion, Maz Mohadjer drives the company toward sustained growth within the competitive life sciences landscape. The Chief Executive Officer maintains rigorous standards for product innovation, ensuring that the firm remains a primary supplier for clinical diagnostics. Through constant evaluation of market trends, the Chief Executive Officer secures the competitive position of the company, ultimately supporting the broader mission of providing essential tools for complex genetic research and development initiatives worldwide.

Alfonso Avila, the Group Chief Executive Officer at Integrated DNA Technologies, manages the complex integration of global business units and regional operational workflows. Focusing on the scalability of manufacturing processes, the Group Chief Executive Officer optimizes supply chain efficiency to meet the high-volume demands of the pharmaceutical industry. This role requires close collaboration with internal departments to streamline production cycles for custom nucleic acids. Alfonso Avila executes strategic initiatives that enhance the company's footprint across international markets, ensuring that regional operations remain synchronized with corporate objectives. By overseeing the deployment of resources across diverse geographic territories, the Group Chief Executive Officer maintains the agility necessary to respond to rapid shifts in clinical diagnostics requirements. The Group Chief Executive Officer drives performance improvements, ensuring that every operational facet supports the company's commitment to precision, reliability, and excellence in the life sciences sector.

Alan M, the Chief Financial Officer at Integrated DNA Technologies, directs the financial planning, risk management, and capital allocation strategies for the organization. Overseeing the fiscal health of the company, the Chief Financial Officer ensures that investments in manufacturing technology and research infrastructure align with long-term growth objectives. This leadership role involves managing complex financial reporting and maintaining transparency with stakeholders across the pharmaceutical and biotechnology sectors. Alan M executes strategies to optimize cost structures, thereby increasing the efficiency of custom nucleic acid production. By analyzing market data and financial performance metrics, the Chief Financial Officer provides the necessary insights to support strategic decision-making at the executive level. The Chief Financial Officer secures the financial stability required to sustain the company's global operations, ensuring that resources remain available to support ongoing innovation and the expansion of services within the life sciences market.

Chuen-Der Lien, the Chief Technology Officer at Integrated DNA Technologies, architects the technical roadmap and innovation strategy for nucleic acid synthesis and manufacturing. Overseeing the research and development division, the Chief Technology Officer drives the creation of advanced molecular biology tools that support academic research and pharmaceutical development. This leadership role involves integrating cutting-edge automation into production lines to increase throughput and accuracy. Chuen-Der Lien manages the technical infrastructure required to maintain the company's status as a leader in custom nucleic acid production. By collaborating with the broader executive team, the Chief Technology Officer ensures that technological advancements directly translate into improved diagnostic capabilities for clients. The Chief Technology Officer monitors emerging scientific trends to keep the company at the forefront of the life sciences industry, consistently refining manufacturing protocols to meet the rigorous demands of modern genetic research and clinical applications.